The NovaSeq X installed base is finally doing what it was sold to do. Illumina's second-quarter results showed the highest-throughput sequencing system launched in 2022 driving consumables growth, instruments growth, and a return to double-digit top-line expansion at a moment when the broader life-sciences customer base is absorbing tariff inflation, a Chinese unreliable-entities designation, and NIH budget pressure. Management framed the print as continued progress toward the return-to-growth and margin goals outlined in late 2024, and the year-to-date numbers are directionally consistent with that story. NovaSeq X cycles typically reward the installed base with high-margin recurring reagent revenue for years after the initial capital sale, which is why consumables, the largest line in the mix, expanded again in the quarter despite a softer mid-throughput category. The result suggests the cycle is real rather than aspirational, and it is the first reading of the year that management can credibly point to as evidence that the late-2024 plan is on track. The reader should treat this as a data point, not a verdict; the second-half reports need to extend the trajectory for the thesis to harden.
Trading conditions around the release frame why the print matters. The equity closed near the upper half of its fifty-two week range, with a low of $88 and a high of $232 framing the print. The recent price sat near $207 on a market capitalization close to $31B and a trailing earnings multiple near forty. The SomaLogic acquisition closed in late January, contributing the first full proteomics-adjacent consumables revenue to the mix. The Board authorized a fresh $1.5B repurchase program in April alongside the remaining capacity from the 2024 authorization. Total buyback authorization stood at roughly $1.78B at quarter end, with management signaling continued repurchase intent through the balance of the year. The combination of installed-base growth, shareholder returns, and a divestiture-complete balance sheet looks like the configuration management has been working toward for several years.
The strongest counterargument remains the macro. Tariff costs tied to Singapore sourcing are still landing in the cost structure, even after a favorable U.S. Supreme Court ruling on IEEPA tariffs, and the Greater China line continued to decline because of the unreliable-entities listing. Gross margin in the quarter improved on a year-over-year basis but only because a prior-year intangible impairment rolled off the comparison; absent that benefit, mix and freight headwinds actually compressed the margin. The thesis rests on consumables growth compounding as the NovaSeq X fleet matures and as SomaLogic integrates, on continued deleveraging, and on management executing the second-half 2026 buyback at the newly authorized scale. The forward variable to track is high-throughput consumables growth, since it carries both the recurring-revenue and gross-margin implications for the entire cycle.